Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Telix Pharma | Sydney | Salute | Ricerca medica e biotecnologica | 8,30 Mrd A$ | 163,7x | 0,82 | 24,87 A$ | 0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 0,6% Rialzo | Fai l’upgrade a Pro+ | |
Mesoblast | Sydney | Salute | Ricerca medica e biotecnologica | 3,38 Mrd A$ | -20,7x | -1,67 | 2,92 A$ | -4,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -37,1% Ribasso | Fai l’upgrade a Pro+ | |
Clarity Pharmaceuticals | Sydney | Salute | Ricerca medica e biotecnologica | 1,33 Mrd A$ | -44,3x | 0,49 | 4,22 A$ | 1,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Opthea | Sydney | Salute | Ricerca medica e biotecnologica | 972,56 Mln A$ | -1,4x | 0,37 | 0,79 A$ | -1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Avita Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 596,69 Mln A$ | -1x | 0,09 | 3,54 A$ | -18,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 30,3% Rialzo | Fai l’upgrade a Pro+ | |
PYC Therapeutics Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 592,59 Mln A$ | -13,2x | 0,45 | 1,28 A$ | -4,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Immutep | Sydney | Salute | Ricerca medica e biotecnologica | 494,55 Mln A$ | -9,3x | -0,6 | 0,34 A$ | -2,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Orthocell Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 340,98 Mln A$ | -39,7x | 3,97 | 1,41 A$ | 12,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Imugene Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 334,68 Mln A$ | -2,1x | 0,01 | 0,05 A$ | 4,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Dimerix | Sydney | Salute | Ricerca medica e biotecnologica | 267,76 Mln A$ | -12,8x | -1,06 | 0,50 A$ | 4,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Race Oncology | Sydney | Salute | Ricerca medica e biotecnologica | 231,04 Mln A$ | -16,1x | 0,49 | 1,33 A$ | -1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Arovella Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 185,39 Mln A$ | -19,4x | -0,61 | 0,17 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
CogState Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 183,31 Mln A$ | 20,9x | 0,38 | 1,06 A$ | -2,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 36,2% Rialzo | Fai l’upgrade a Pro+ | |
Paradigm Biopharmaceuticals Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 164,23 Mln A$ | -2,3x | -0,65 | 0,47 A$ | 4,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
LTR Pharma | Sydney | Salute | Ricerca medica e biotecnologica | 134,83 Mln A$ | -34x | 0,02 | 0,78 A$ | 4,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Pacific Edge | Sydney | Salute | Ricerca medica e biotecnologica | 96,16 Mln A$ | -3,8x | -0,39 | 0,14 A$ | 3,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Proteomics Intl Labs | Sydney | Salute | Ricerca medica e biotecnologica | 94,32 Mln A$ | -14,1x | -3,65 | 0,71 A$ | -3,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -31% Ribasso | Fai l’upgrade a Pro+ | |
Argenica Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 80,70 Mln A$ | -15,1x | -0,79 | 0,62 A$ | -1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Actinogen Medical | Sydney | Salute | Ricerca medica e biotecnologica | 79,91 Mln A$ | -4,3x | 12,25 | 0,03 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cynata Therapeutics Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 54,06 Mln A$ | -4,3x | -0,1 | 0,24 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Neurotech Intl | Sydney | Salute | Ricerca medica e biotecnologica | 53,80 Mln A$ | -8,7x | -0,26 | 0,05 A$ | -1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Anteo Diagnostics | Sydney | Salute | Ricerca medica e biotecnologica | 53,30 Mln A$ | -5x | -0,16 | 0,02 A$ | 11,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Alterity Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 53,20 Mln A$ | -2x | -0,35 | 0,010 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Tryptamine Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 49,78 Mln A$ | -2,6x | -0,54 | 0,04 A$ | -2,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bioxyne Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 49,18 Mln A$ | -3,4x | 0,01 | 0,02 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
IDT Australia Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 47,28 Mln A$ | -6,6x | -0,14 | 0,11 A$ | 7,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Prescient Therapeutics Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 40,27 Mln A$ | -5x | 0,77 | 0,05 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Clever Culture Systems | Sydney | Salute | Ricerca medica e biotecnologica | 35,15 Mln A$ | -5x | -0,1 | 0,02 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Amplia Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 29,11 Mln A$ | -3x | 0,26 | 0,08 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Island Pharmaceuticals | Sydney | Salute | Ricerca medica e biotecnologica | 29,06 Mln A$ | -2,5x | -1,21 | 0,17 A$ | 7,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -11,1% Ribasso | Fai l’upgrade a Pro+ |